F2G: Medical referenceAntifungal drug developer F2G Ltd has appointed distinguished research scientist John Rex to the position of Chief Medical Officer. more ➔
Merck: Strategic hikeAt the beginning of October, Isabel De Paoli assumed the position of Chief Strategy Officer at German healthcare company Merck GmbH. She will head the Group Strategy and Transformation Function, which … more ➔
Pharmalink: Gaining momentumIn order to prepare for the start of Phase III trials with its lead drug candidate Nefecon, Pharmalink AB has made several new appointments. Among them Kari Sandvold, who will take over as Vice President … more ➔
Symphogen: Big shoes to fillCopenhagen-based Symphogen is losing its long-time CEO Kirsten Drejer, who co-founded the Danish antibody specialist in 2000. In her place, erstwhile CFO Martin Olin is taking over the helm. more ➔
Enterprise Therapeutics: Vital serviceEpidarex Capital-backed respiratory disease start-up Enterprise Therapeutics has named biotech entrepreneur John Ford as its new CEO. Ford previously co-founded Xention, Ario Pharma, and Metrion Biosciences. more ➔
Confo Therapeutics: Time for changeConfo Therapeutics wants to metamorphose from a tech company to a drug discovery company, and it has hired Cedric Ververken to guide the transition. more ➔
Arquer Diagnostics: New head for DxDiagnostics company Arquer Diagnostics Ltd (Sunderland, UK) has appointed Nadia Whittley as CEO, replacing Ian Campbell with immediate effect. Whittley will be responsible for launching the company’s … more ➔
Novo Nordisk: Passing the batonLars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development at Novo Nordisk, will take over the helm of the Danish diabetes major. He takes over from long-time CEO … more ➔
Acesion Pharma: New head of financeDanish biotech Acesion Pharma has hired Jakob Dynnes Hansen as its Chief Financial Officer. He joins from Evolva, a Swiss biotech company, where he has been CFO since 2007. more ➔
PharmaMar: Pushing the bordersPharmaMar is driving the expansion of its US operations. To this end, the company has appointed Pascal Besman to the newly created role of Chief Operation Officer of the marine-derived oncology drug … more ➔
